Compare ARDX & LCLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ARDX | LCLN |
|---|---|---|
| Founded | 2007 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 797.8M | 821.7M |
| IPO Year | 2014 | 2026 |
| Metric | ARDX | LCLN |
|---|---|---|
| Price | $3.02 | $25.88 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 7 |
| Target Price | $12.80 | ★ $27.07 |
| AVG Volume (30 Days) | ★ 4.3M | 222.4K |
| Earning Date | 11-03-2026 | 11-05-2026 |
| Dividend Yield | N/A | ★ 1.08% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,607,000.00 | N/A |
| Revenue This Year | $19.21 | $28.20 |
| Revenue Next Year | $28.19 | $15.26 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.96 | $20.05 |
| 52 Week High | $8.40 | $27.55 |
| Indicator | ARDX | LCLN |
|---|---|---|
| Relative Strength Index (RSI) | 40.04 | 64.18 |
| Support Level | N/A | $22.92 |
| Resistance Level | $3.35 | $27.49 |
| Average True Range (ATR) | 0.12 | 0.86 |
| MACD | 0.01 | 0.26 |
| Stochastic Oscillator | 25.32 | 90.85 |
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
Lincoln International Inc is an independent investment banking advisory company focused on private capital markets. The company operates its business through its two operating segments: Investment Banking Advisory and Valuations and Opinions. The Investment Banking Advisory segment offers a range of services related to mergers and acquisitions, with key areas of focus including sell-side advisory, buy-side advisory, asset sales and divestitures, restructuring, primary and secondary capital raising, and merger-related engagements. The Valuations and Opinions segment provides valuation services to investment funds and financial institutions. The majority of revenue is derived from the Investment Banking Advisory segment. Geographically, the maximum revenue is derived from the Americas.